Clinical Trials Logo

Relapsing-Remitting clinical trials

View clinical trials related to Relapsing-Remitting.

Filter by:
  • None
  • Page 1

NCT ID: NCT04966338 Completed - Multiple Sclerosis Clinical Trials

Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis

Start date: August 19, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Ocrelizumab produced by CinnaGen compared with Ocrevus® (Roche, Switzerland) in subjects with relapsing remitting multiple sclerosis (RRMS). All the participants will receive one of the following regimens: Ocrelizumab (CinnaGen) or Ocrevus® (Roche, Switzerland) ,600 mg (given as dual infusions of ocrelizumab 300 mg on Days 1 and 15 of the first 24-week treatment cycle and as single infusions of 600 mg on Day 1 for each 24-week treatment cycle, thereafter) every 24 weeks. The primary objective of this study is to verify the equivalency of Ocrelizumab (CinnaGen) versus Ocrevus® (Roche, Switzerland) in reducing the annualized relapse rate (ARR) in participants with relapsing remitting multiple sclerosis (RRMS) at 2 years.

NCT ID: NCT01905527 Terminated - Multiple Sclerosis Clinical Trials

Adherence Trial With MS LifeLines ® Services

Start date: July 2013
Phase: N/A
Study type: Observational

This is a Phase IV study to compare the current level of MS LifeLines ® (MSLL) services (face-to-face nursing visits and phone contacts) with customized MSLL services, to determine the optimal services to enhance medication adherence and treatment persistence with Rebif ® subcutaneous three times a week.

NCT ID: NCT01791244 Completed - Multiple Sclerosis Clinical Trials

A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmartâ„¢ Device

RebiQoL
Start date: February 2013
Phase: Phase 4
Study type: Interventional

This is a randomized, comparative, and multicenter study to assess the impact of a patient support program (MinSupport Plus) on health related quality of life (HRQoL) and adherence in subjects with relapsing-remitting multiple sclerosis administered Rebif® with the RebiSmartâ„¢ device.

NCT ID: NCT01578330 Completed - Multiple Sclerosis Clinical Trials

A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720

Start date: October 2012
Phase: Phase 4
Study type: Interventional

The study will assess the patients' satisfaction of treatment after 12 months treatment with fingolimod It also will assess the tolerability profile of fingolimod in a small population.

NCT ID: NCT00893217 Completed - Multiple Sclerosis Clinical Trials

BEYOND Pilot Study

Start date: November 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to valuate safety and tolerability of Betaseron.